IP Library Granted Patent US 8,227,190
Granted Patent B2
US 8,227,190 · App. 11/753,454 · Granted Jul 24, 2012

Approach to molecular diagnosis of human papillomavirus-related diseases

Assignee: Qiagen Gaithersburg, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,227,190
App. No.
11/753,454
Granted
Jul 24, 2012
Kind
B2
Abstract

The present invention relates to an accurate, sensitive, and efficient sequential or concurrently sequential method for molecular diagnosis of human papillomavirus (HPV)-based disease, where the method improves the accuracy and reliability of diagnostic and prognostic assessments of HPV-based disease. The method of the invention comprises a primary screen of a sample for HPV nucleic acids, followed by a secondary screen for molecular markers, such as proliferation and cell cycle control group protein markers. The sequential or concurrently sequential method significantly reduces the number of false positive results.

Claims (6)

1. A kit for detecting high risk HPV nucleic acids and subsequently detecting protein marker expression in a sample, comprising reagents for detecting molecular characteristics in a biological sample, wherein the reagents consist essentially of at least two probes capable of detecting high risk HPV nucleic acids in a sample, at least two primary antibodies that are specific to two different protein markers, wherein the protein markers are selected from the group consisting of: PCNA and Ki-67, PCNA and p16, and PCNA, Ki-67 and p16.

2. The kit according to claim 1 , wherein the at least two probes are selected from the group consisting of a DNA probe and an RNA probe.

3. The kit of claim 1 , wherein the kit further comprises instructions for detecting the HPV nucleic acids by hybridization under low stringency conditions.

4. The kit of claim 1 , wherein the protein markers are PCNA and Ki-67.

5. The kit of claim 1 , wherein the protein markers are PCNA and p16.

6. The kit of claim 1 , wherein the protein markers are PCNA, Ki-67 and p16.

Assignments (1)
CHANGE OF NAME Recorded Jun 20, 2012
From: DIGENE CORPORATION
To: QIAGEN GAITHERSBURG, INC.
Reel/Frame 028409/0015 →
Continuity (2)
Continuation 10411830 · Apr 11, 2003
Related Publication 20070243552A1 · Oct 18, 2007